Compatibility Studies of Sildenafil-HPBCD Inclusion Complex with Pharmaceutical Excipients.

ABSTRACT: Background/Objectives: In the past two decades, the primary therapeutic use of sildenafil has shifted significantly, from the treatment of angina to managing erectile dysfunction, and since the early 2000s it has been used in the treatment of pulmonary hypertension, particularly pulmonary arterial hypertension. Sildenafil is used as a citrate salt; after oral administration, it presents an absorption of ~90% and an absolute bioavailability of 38%, due to the first-pass effect, such that it belongs to class II of the Biopharmaceutics Classification System. Currently, studies are seeking to obtain new pharmaceutical formulations with an optimized biopharmaceutical profile. In this study, an inclusion complex of sildenafil citrate and 2-hydroxypropyl-beta-cyclodextrin in a molar ratio

SUBMITTER: Bertici RA 

PROVIDER: S-EPMC12473755 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature